Infanrix Vaccine Description
Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children aged 6 weeks.
Infanrix active ingredients are non-infectious substances from tetanus, diphtheria bacteria, and purified proteins of pertussis bacteria. Each 0.5 mL dose contains: 30 IU (25 Lf U) of diphtheria toxoid.
Infanrix Vaccine Indication
Infanrix is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to seventh birthday).
Infanrix Vaccine Dosage
Infanrix is approved for intramuscular administration in infants and children 6 weeks to 7 years of age (prior to the seventh birthday) as a 5-dose series
- A primary immunization course of 3 doses administered at 2, 4, and 6 months of age (at intervals of 4 to 8 weeks). The first dose may be given as early as 6 weeks of age
- Followed by 2 booster doses, administered at 15 to 20 months of age and at 4 to 6 years of age
Preferred administration site:
- Anterolateral aspect of the thigh for most infants younger than 12 months of age
- Deltoid muscle of the upper arm for most children 12 months of age to 7 years of age
Infanrix Vaccine News
October 31, 2019 - GSK Korea announced its newly launched Infanrix IPV-Hib, a quintuplet vaccine that covers diphtheria, tetanus, pertussis, polio and Haemophilus influenzae type b (Hib). The company hopes that by adding efficiency to the excellence of the existing Infanrix brand, it can become a vaccine that leads to the prevention of disease for infants and toddlers, said Professor Lee Jin of the Department of Pediatrics at Hanil Hospital.